# Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DAT-1604 in Advanced Solid Tumor

Source: https://onco.cc/trials/nct06998173/  
OnCo record `nct06998173` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of DAT-1604 run by Danatlas Pharmaceuticals Co., Ltd, not yet recruiting.

## Summary

Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DAT-1604 in Advanced Solid Tumor is a phase 1 interventional study registered as NCT06998173 by Danatlas Pharmaceuticals Co., Ltd, with 228 participants planned, started 2025-07-31. Conditions recorded: Advanced Solid Tumors. Interventions recorded: DAT-1604 tablet.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06998173
- Phase: 1
- Setting: Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DAT-1604 Tablets as Monotherapy in the Advanced Solid Tumor
- Sponsor: Danatlas Pharmaceuticals Co., Ltd
- Enrolled: 228

## Sources

- ClinicalTrials.gov NCT06998173: https://clinicaltrials.gov/study/NCT06998173

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [DAT-1604](https://onco.cc/drugs/dat-1604/)
- companies: [Danatlas Pharmaceuticals](https://onco.cc/companies/danatlas-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct06998173.json